Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:BMEA NASDAQ:ITOS NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.94+0.6%$15.13$8.04▼$25.88$484.44M2.39706,253 shs469,300 shsBMEABiomea Fusion$1.86+2.8%$1.78$1.29▼$13.07$107.71M-0.13531,478 shs417,576 shsITOSiTeos Therapeutics$10.15$10.16$4.80▼$17.63$448.73M1.311.51 million shsN/ARGNXREGENXBIO$9.89+4.3%$8.71$5.03▼$13.48$478.88M1.17631,039 shs329,551 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.56%+7.43%+50.63%+44.21%-5.58%BMEABiomea Fusion+2.76%-8.37%+20.78%-25.60%-72.97%ITOSiTeos Therapeutics0.00%0.00%+0.40%+1.50%-34.77%RGNXREGENXBIO+4.32%+8.44%+25.99%-3.04%-13.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.94+0.6%$15.13$8.04▼$25.88$484.44M2.39706,253 shs469,300 shsBMEABiomea Fusion$1.86+2.8%$1.78$1.29▼$13.07$107.71M-0.13531,478 shs417,576 shsITOSiTeos Therapeutics$10.15$10.16$4.80▼$17.63$448.73M1.311.51 million shsN/ARGNXREGENXBIO$9.89+4.3%$8.71$5.03▼$13.48$478.88M1.17631,039 shs329,551 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.56%+7.43%+50.63%+44.21%-5.58%BMEABiomea Fusion+2.76%-8.37%+20.78%-25.60%-72.97%ITOSiTeos Therapeutics0.00%0.00%+0.40%+1.50%-34.77%RGNXREGENXBIO+4.32%+8.44%+25.99%-3.04%-13.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57181.89% UpsideBMEABiomea Fusion 3.17Buy$14.80695.70% UpsideITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsideRGNXREGENXBIO 2.83Moderate Buy$28.38186.91% UpsideCurrent Analyst Ratings BreakdownLatest BMEA, ARCT, RGNX, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.009/8/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/19/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.008/11/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.008/8/2025RGNXREGENXBIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $17.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M3.20N/AN/A$8.90 per share2.02BMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/AITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91RGNXREGENXBIO$83.33M5.99N/AN/A$5.24 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)BMEABiomea Fusion-$138.43M-$3.03N/AN/AN/AN/A-243.95%-140.74%11/4/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)Latest BMEA, ARCT, RGNX, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/7/2025Q2 2025RGNXREGENXBIO-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 million8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A8/5/2025Q2 2025BMEABiomea Fusion-$0.59-$0.51+$0.08-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90BMEABiomea FusionN/A3.683.68ITOSiTeos TherapeuticsN/A7.537.53RGNXREGENXBION/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BMEABiomea Fusion96.72%ITOSiTeos Therapeutics97.16%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%BMEABiomea Fusion18.42%ITOSiTeos Therapeutics14.20%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableBMEABiomea Fusion5059.51 million48.55 millionOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionableRGNXREGENXBIO37050.51 million44.05 millionOptionableBMEA, ARCT, RGNX, and ITOS HeadlinesRecent News About These CompaniesREGENXBIO (NASDAQ:RGNX) Earns Buy Rating from HC Wainwright2 hours ago | americanbankingnews.comChardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)2 hours ago | americanbankingnews.comA Glimpse Into The Expert Outlook On Regenxbio Through 6 AnalystsSeptember 9 at 9:31 AM | benzinga.comRegenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter SyndromeSeptember 9 at 7:09 AM | seekingalpha.comREGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8 at 2:26 PM | seekingalpha.com50,969 Shares in REGENXBIO Inc. $RGNX Purchased by Ieq Capital LLCSeptember 8 at 3:51 AM | marketbeat.comInvesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNXSeptember 7 at 3:03 AM | marketbeat.comREGENXBIO reports positive data from Hunter syndromeSeptember 6, 2025 | msn.comRegenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trialSeptember 6, 2025 | msn.comRegenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter SyndromeSeptember 6, 2025 | seekingalpha.comREGENXBIO Inc. $RGNX Shares Acquired by PDT Partners LLCSeptember 6, 2025 | marketbeat.comREGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IISeptember 5, 2025 | prnewswire.comTrexquant Investment LP Purchases 308,516 Shares of REGENXBIO Inc. $RGNXSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 162,423 Shares of REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comHsbc Holdings PLC Sells 29,002 Shares of REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comNuveen LLC Makes New Investment in REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comREGENXBIO Inc. $RGNX Shares Sold by Jump Financial LLCSeptember 2, 2025 | marketbeat.comVanguard Group Inc. Has $24.83 Million Stock Position in REGENXBIO Inc. $RGNXAugust 31, 2025 | marketbeat.comAlphaQuest LLC Increases Stock Holdings in REGENXBIO Inc. $RGNXAugust 29, 2025 | marketbeat.comREGENXBIO to Participate in Upcoming Investor ConferencesAugust 28, 2025 | prnewswire.comAlgert Global LLC Takes $354,000 Position in REGENXBIO Inc. $RGNXAugust 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMEA, ARCT, RGNX, and ITOS Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$17.94 +0.10 (+0.56%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$18.00 +0.05 (+0.31%) As of 09/9/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Biomea Fusion NASDAQ:BMEA$1.86 +0.05 (+2.76%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.83 -0.03 (-1.61%) As of 09/9/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.iTeos Therapeutics NASDAQ:ITOS$10.15 0.00 (0.00%) As of 08/29/2025iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.REGENXBIO NASDAQ:RGNX$9.89 +0.41 (+4.32%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$9.89 0.00 (0.00%) As of 09/9/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
